Reversal of retinal ganglion cell dysfunction happens after IOP reduction

Article

A study has shown that the surgical reduction of IOP causes the reversal of retinal ganglion cell (RGC) dysfunction.

A study has shown that the surgical reduction of IOP causes the reversal of retinal ganglion cell (RGC) dysfunction. It was also found that the pattern electroretinogram optimized for glaucoma screening (PERGLA) can be a non-invasive technique to measure RGC function.

Mitra Sehi, Research Assistant Professor of Ophthalmology at Bascom Palmer Eye Institute, University of Miami, USA, conducted a prospective cohort study of 47 eyes of 47 patients with uncontrolled IOP. The patients underwent a total ocular examination, arterial blood pressure, standard automated perimetry (SAP) and PERGLA before surgery and three months after surgery.

The results indicated that mean postoperative IOP was significantly reduced compared with preoperative IOP. PERGLA amplitude after surgery increased compared to preoperative PERGLA amplitude. Thirty-four of the 47 eyes underwent trabeculectomy with antifibrosis therapy, 13 eyes had glaucoma drainage implant surgery.

The conclusion was that the reversal of RGC dysfunction happens after surgical reduction of IOP and can be measured using PERGLA.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.